The Utility of P300 As a Schizophrenia Endophenotype and Predictive Biomarker: Clinical and Socio-Demographic Modulators in COGS-2
Schizophrenia Research 163 (2015) 53–62 Contents lists available at ScienceDirect Schizophrenia Research journal homepage: www.elsevier.com/locate/schres The utility of P300 as a schizophrenia endophenotype and predictive biomarker: Clinical and socio-demographic modulators in COGS-2 Bruce I. Turetsky a,⁎, Erich M. Dress a, David L. Braff b,c,MonicaE.Calkinsa, Michael F. Green d,e, Tiffany A. Greenwood b, Raquel E. Gur a, Ruben C. Gur a, Laura C. Lazzeroni f, Keith H. Nuechterlein d, Allen D. Radant g,h, Larry J. Seidman i,j, Larry J. Siever k,l, Jeremy M. Silverman k,l, Joyce Sprock b, William S. Stone i,j, Catherine A. Sugar m, Neal R. Swerdlow b, Debby W. Tsuang g,h, Ming T. Tsuang b,n,o, Gregory Light b,c a Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA b Department of Psychiatry, University of California San Diego, La Jolla, CA, USA c VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, USA d Department of Psychiatry and Biobehavioral Sciences, Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA e VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA f Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA, USA g Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA h VA Puget Sound Health Care System, Seattle, WA, USA i Department of Psychiatry, Harvard Medical School, Boston, MA, USA j Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Boston, MA, USA k Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY, USA l James J.
[Show full text]